| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IT | Common Stock | Options Exercise | $1,887,160 | +13,196 | +18% | $143.01 | 84,740 | 31 Jul 2024 | Direct | F1 |
| transaction | IT | Common Stock | Disposed to Issuer | $1,887,482 | -3,766 | -4.4% | $501.19 | 80,974 | 31 Jul 2024 | Direct | F2 |
| transaction | IT | Common Stock | Tax liability | $2,412,729 | -4,814 | -5.9% | $501.19 | 76,160 | 31 Jul 2024 | Direct | F3 |
| transaction | IT | Common Stock | Options Exercise | $771,550 | +5,000 | +6.6% | $154.31 | 81,160 | 31 Jul 2024 | Direct | F1 |
| transaction | IT | Common Stock | Disposed to Issuer | $771,833 | -1,540 | -1.9% | $501.19 | 79,620 | 31 Jul 2024 | Direct | F2 |
| transaction | IT | Common Stock | Tax liability | $885,102 | -1,766 | -2.2% | $501.19 | 77,854 | 31 Jul 2024 | Direct | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IT | Stock Appreciation Rights | Options Exercise | $0 | -13,196 | -100% | $0.000000* | 0 | 31 Jul 2024 | Common Stock | 13,196 | $143.01 | Direct | F4 |
| transaction | IT | Stock Appreciation Rights | Options Exercise | $0 | -5,000 | -19% | $0.000000 | 20,657 | 31 Jul 2024 | Common Stock | 5,000 | $154.31 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | Represents shares acquired upon exercise of SARs. |
| F2 | Represents shares withheld that had an aggregate value, based on the market price on the date of exercise, substantially equal to the aggregate exercise price of the SARs. |
| F3 | Represents shares withheld for the payment of applicable income and payroll withholding taxes. |
| F4 | These SARs are part of an award that became exercisable in four substantially equal annual installments, commencing on February 6, 2020, and are fully exercisable. |
| F5 | These SARs are part of an award that became exercisable in four substantially equal annual installments, commencing on February 5, 2021, and are fully exercisable. |